Previous Close | 2.1700 |
Open | 2.1600 |
Bid | 2.0900 x 2300 |
Ask | 2.2200 x 3000 |
Day's Range | 2.1600 - 2.1900 |
52 Week Range | 1.8000 - 2.7200 |
Volume | 34,380 |
Avg. Volume | 159,204 |
Market Cap | 63.625M |
Beta | 0.67 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1730 |
Earnings Date | Mar 26, 2018 - Mar 30, 2018 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.00 |
Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. Sophiris is currently conducting a Phase 2b clinical trial of topsalysin in patients with localized clinically significant prostate cancer (NCT03081481).
SAN DIEGO and VANCOUVER, British Columbia , March 21, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...
SAN DIEGO and VANCOUVER, British Columbia , March 15, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...
SAN DIEGO and VANCOUVER, British Columbia , Dec. 27, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...
SAN DIEGO and VANCOUVER, British Columbia, Dec. 11, 2017 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris") today announced that it has completed enrollment in its Phase 2b study to evaluate the safety and tolerability of topsalysin in treating men with clinically significant localized prostate cancer. "I am delighted that Sophiris has completed enrollment into its multi-center Phase 2b study. My thanks to the men and my colleagues in each clinical trial center for recognizing the potential of topsalysin to focally treat localized, clinically significant prostate cancer with a minimally invasive, targeted, short duration procedure," said Professor Hashim Ahmed, Chair of Urology, Imperial College London & Imperial College Healthcare NHS Trust and an investigator in the study.
SAN DIEGO and VANCOUVER, British Columbia , Nov. 27, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...
While small-cap stocks, such as Sophiris Bio Inc (NASDAQ:SPHS) with its market cap of USD $61.57M, are popular for their explosive growth, investors should also be aware of their balanceRead More...
As expected, the company did not report any revenues during the quarter. The company reported a net loss of $2.7 million, or $0.09 per share. The increase was due to costs associated with the Phase 2b trial of topsalysin in prostate cancer along with increased manufacturing costs.
SAN DIEGO and VANCOUVER, British Columbia , Nov. 9, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...
SAN DIEGO and VANCOUVER, British Columbia, Oct. 2, 2017 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris") today provided an update on clinical trial enrollment of its Phase 2b study of topsalysin as a treatment for men with clinically significant localized prostate cancer. Patient enrollment is near completion, and the remaining patients are being scheduled to receive treatment within the next few weeks. Sophiris expects the study will be fully enrolled by the end of October.
SAN DIEGO and VANCOUVER, British Columbia, Sept. 13, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that it entered into a loan and security agreement with Silicon Valley Bank and may borrow up to $10 million in two term loans. "We plan to utilize the proceeds from this loan to fund the manufacturing for Phase 3 clinical trial materials and expect that it will allow us to extend our cash runway to the middle of 2019 and provide additional financial flexibility as we advance topsalysin through clinical development," said Randall E. Woods, president and CEO of Sophiris.
SAN DIEGO and VANCOUVER, British Columbia, Aug. 17, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference.
By David Bautz, PhD NASDAQ:SPHS Financial Update On August 10, 2017, Sophiris (NASDAQ:SPHS) announced financial results for the second quarter of 2017. As expected, the company did not report any revenues ...
SAN DIEGO and VANCOUVER, British Columbia , Aug. 10, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a late stage clinical biopharmaceutical company ...
SAN DIEGO and VANCOUVER, British Columbia, June 23, 2017 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris"), a late stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases, today announced that it has been added to the Russell Microcap® Index, effective after the close of market on June 23, 2017. The Russell Microcap® Index represents 2,000 small cap and micro-cap stocks that captures the smallest 1,000 companies in the Russell 2000®, in addition to 1,000 smaller U.S.- based listed stocks. Russell indices are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies.
SAN DIEGO and VANCOUVER, British Columbia, June 8, 2017 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris") today announced that the first patient has been dosed in its Phase 2b study to evaluate the safety and tolerability of topsalysin in focally treating men with clinically significant localized prostate cancer. This Phase 2b study will build on the successful Phase 2a proof-of-concept study for the treatment of localized prostate cancer which demonstrated that a targeted intraprostatic administration of topsalysin has the potential to safely ablate prostate tumor cells. "Topsalysin has the potential to provide a much-needed opportunity to treat the patients who have clinically significant localized prostate cancer in a targeted focal manner, ablate pre-identified lesions and downgrade the patient to non-significant cancer," said Dr. Hashim Ahmed, professor and chair of urology, Imperial College London.
SAN DIEGO and VANCOUVER, British Columbia, May 23, 2017 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris"), a late stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases, today reported that it has received the regulatory clearance for the diluent – the medium in which topsalysin is diluted. Clinical sites can now begin dosing eligible patients in a Phase 2b study in localized prostate cancer. Sophiris Bio Inc. is a late-stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases.
Sophiris Bio, Inc. (SPHS) is developing treatments for lower urinary tract symptoms of benign prostatic hyperplasia (BPH) and localized clinically significant low to intermediate risk prostate cancer. The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland.
SAN DIEGO and VANCOUVER, British Columbia, May 15, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a late stage clinical biopharmaceutical company ...
SAN DIEGO and VANCOUVER, British Columbia, May 15, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a late-stage clinical biopharmaceutical company ...